Company / R&D per Share
Inhibikase Therapeutics, Inc. R&D per Share History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.20
FY2024
5-year range
$0.09 / $2.85
FY2021-FY2024
Trend
-22.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.45 to $2.20 over the past 2 years.
Based on SEC 10-K filings.
2.20 in FY2024 with a 3-year CAGR of +191.4%.
Improved from $0.45 to $2.20 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +191.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, r&d per share decreased 22.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.20 | -22.7% |
| FY2023 | $2.85 | +530.9% |
| FY2022 | $0.45 | +407.8% |
| FY2021 | $0.09 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026